Second International Conference on Cancer Vaccines/Adjuvants/Delivery for the Next Decade (CVADD): Heidelberg, Germany, 10-12 October 2007

/in , , /von

PMID: 18270701
Journal: Cancer immunology, immunotherapy : CII (volume: 57, issue: 9, Cancer Immunol. Immunother. 2008 Sep;57(9):1421-7)
Published: 2008-02-13

Authors:
Schirrmacher V, Beckhove P, Fournier P, Umansky V

ABSTRACT

Open in PubMed

Das könnte Dich auch interessieren
Targeting of IL-2 and GM-CSF immunocytokines to a tumor vaccine leads to increased anti-tumor activity
Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM…
TNF-related apoptosis-inducing ligand mediates tumoricidal activity of human monocytes stimulated by Newcastle disease virus
The hemagglutinin-neuraminidase gene of Newcastle Disease Virus: a powerful molecular adjuvant for DNA anti-tumor vaccination
Selective gene transfer in vitro to tumor cells via recombinant Newcastle disease virus
Autologous tumor cell vaccines for post-operative active-specific immunotherapy of colorectal carcinoma: long-term patient survival and mechanism of…